SBIR/STTR Research Award

Vaccine discovery for Burkholderia via protection screen

Award identifier c5f3e7c157db85590728b13b263cb2263d4dcd51caa4a370309287f0045cc17bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$500,000

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MACROGENICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
V6KCS3B53JN8
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Glanders is a severe disease that has already been used as a bioweapon. It is naturally an equine disease but can be administered by aerosol for efficient human infection. Even if quickly diagnosed as Burkholderia mallei and treated, antibiotics do not control infections well. No vaccine has been developed, yet is a rational component of any plan for defense. It is increasingly clear that both safe and efficacious vaccines of the future should be based on subunit designs. Therefore, we propose to identify new, subunit vaccine candidates against glanders. We have engaged in a genomic-scale search of all B. mallei coding sequences for protective antigens. Using an aerosol challenge with virulent pathogen, we have sifted 200,000 genomic fragments to a number of lower complexity pools that protect hamsters and mice against lethal disease. This was accomplished by expression library immunization. Our specific approach to developing one or more subunit vaccines will be to 1) reduce the expression library to its individual protective components, 2) to characterize the immune responses correlated with protection and 3) prepare these new B. mallei antigens, and their homologs from the very closely related B. pseudomalllei, in three vaccine delivery modes. These compositions will be intended for testing in the relevant horse and monkey hosts in phase II of this proposal. At the conclusion of this phase I project we will have generated protective subunits and formulated them into three modalities for B. mallei, and perhaps B. pseudomallei, vaccines. The immune responses correlated with protection will be defined, which should facilitate optimal development of this vaccine and those for related pathogens, such as some Brucella and Pseudomonas species.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

11 SBIR/STTR records share this UEI (2002–2004). Reported award amounts total $2,573,564. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.